Welcome to our dedicated page for Zentalis Pharmaceuticals news (Ticker: ZNTL), a resource for investors and traders seeking the latest updates and insights on Zentalis Pharmaceuticals stock.
Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) is a clinical-stage biopharmaceutical company focused on oncology, and its news flow centers on the development of azenosertib (ZN‑c3), an investigational WEE1 inhibitor. Company updates highlight progress in Cyclin E1-positive platinum-resistant ovarian cancer (PROC), where azenosertib is the lead program, as well as exploratory work in other tumor types and combination regimens.
Visitors to this ZNTL news page can follow announcements on the DENALI Phase 2 trial, a multi-part, registration-intent study in PROC. Zentalis uses press releases to report milestones such as completion of enrollment in DENALI Part 2a, dose confirmation plans, and expectations for topline data from Part 2, which the company states could support a potential accelerated approval pathway, subject to FDA feedback. News items also describe alignment with the U.S. Food and Drug Administration on the design of ASPENOVA, a planned Phase 3 randomized, confirmatory trial comparing azenosertib to standard-of-care chemotherapy in Cyclin E1-positive PROC.
Beyond ovarian cancer, Zentalis news covers scientific presentations and broader development activity for azenosertib, including Phase 1 data in advanced solid tumors, Cyclin E1 biomarker findings, the TETON Phase 2 trial in uterine serous carcinoma, and a Phase 1 combination study with trastuzumab deruxtecan in HER2-expressing cancers. The company also issues regular financial results and operational progress releases, detailing research and development spending, cash position, and restructuring steps intended to prioritize late-stage development of azenosertib.
Additional ZNTL headlines include corporate governance and personnel changes, such as leadership transitions in the Chief Legal Officer role, board resignations, and equity inducement grants under Nasdaq Listing Rule 5635(c)(4). Investors and observers can use this page to monitor how Zentalis links its clinical milestones, biomarker strategy and financial resources as it advances azenosertib in PROC and other tumor settings.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced a Key Opinion Leader (KOL) virtual meeting on September 24, 2020, focused on its WEE1 inhibitor, ZN-c3, for treating advanced solid tumors. Presenters include Dr. Kwok-Kin Wong and Dr. Gordon Mills, who will discuss the ongoing clinical strategy and the potential of ZN-c3 in cancer treatment. ZN-c3 aims to induce DNA damage in cancer cells to promote cell death and prevent tumor growth. A Phase 1/2 trial is underway, with plans for a Phase 1b trial combining ZN-c3 with chemotherapy in advanced ovarian cancer.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced that CEO Anthony Sun will speak at two virtual investor conferences on September 17, 2020. The events are the Morgan Stanley 18th Annual Global Healthcare Conference at 8:45 a.m. ET and the Cantor Fitzgerald Virtual Global Healthcare Conference at 10:00 a.m. ET. Both presentations will be webcast live on Zentalis' website. The company focuses on developing small molecule therapeutics targeting cancer pathways, with a promising pipeline including ZN-c5 for breast cancer and other inhibitors.
On August 13, 2020, Zentalis Pharmaceuticals (ZNTL) announced key financial results for Q2 2020, highlighted by a successful IPO raising ~$190 million and a follow-on offering generating ~$144.4 million. The company also completed a $20 million Series A financing for its joint venture, Zentera Therapeutics. Strategic collaborations with Eli Lilly and Tavros Therapeutics were established to enhance their oncology pipeline. Despite a net loss of $27.3 million, Zentalis maintains a strong cash position of $233.2 million, which is expected to fund operations into 2023.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) has announced a public offering of 4,125,000 shares of common stock at $35.00 per share, aiming for total gross proceeds of approximately $144.4 million. The offering is set to close on August 3, 2020, subject to customary conditions. Additionally, underwriters have a 30-day option to purchase up to 618,750 extra shares.
The effective registration statement was filed with the U.S. SEC on July 29, 2020. Zentalis focuses on developing small molecule therapeutics targeting cancer.
Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) announced a public offering of 3,750,000 shares of its common stock, with an additional 562,500 shares available for underwriters. The offering, managed by Morgan Stanley, Jefferies, SVB Leerink, and Guggenheim Securities, aims to provide funding for the company's oncology product development. While the registration statement has been filed with the SEC, it is not yet effective. Proceeds from the sale will potentially support their ongoing research and development in cancer therapeutics.
Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) announced a clinical collaboration with Eli Lilly to evaluate ZN-c5, a selective estrogen receptor degrader, in combination with Lilly's Verzenio for treating ER+/HER2- advanced breast cancer. This study aims to assess the potential of ZN-c5 alongside a CDK4 and 6 inhibitor, building upon existing therapies. Zentalis will conduct the trial while retaining ownership of ZN-c5, with Lilly providing Verzenio doses. ZN-c5 is currently in a Phase 1/2 trial as a monotherapy and with palbociclib, another collaboration with Pfizer.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) has appointed Dr. Kimberly Blackwell to its Board of Directors. A seasoned breast cancer researcher, Dr. Blackwell brings over 20 years of experience in the biopharmaceutical sector. Her previous roles include Chief Medical Officer at Tempus and Vice President of Early Phase Oncology at Eli Lilly. Dr. Blackwell's expertise in oncology will be crucial for advancing Zentalis's oncology pipeline. The company is focused on developing small molecule therapeutics targeting cancer pathways, including promising candidates like ZN-c5 and ZN-c3.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced the presentation of preclinical data on ZN-c5 at the AACR Virtual Annual Meeting II from June 22-24, 2020. ZN-c5, an oral selective estrogen receptor degrader, showed anti-tumor activity in breast cancer models and favorable oral bioavailability across species. Currently under evaluation in a Phase 1/2 trial for ER+/HER2- advanced breast cancer, ZN-c5 may pave the way for improved treatment options in oncology.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced that its CEO, Anthony Sun, MD, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on June 4, 2020, at 1:30 p.m. ET. A live webcast will be available on the company’s website, with an archived version accessible afterwards.
Zentalis focuses on developing novel small molecule therapeutics targeting cancer pathways, including its lead program, ZN-c5, an oral selective estrogen receptor degrader for breast cancer. For more information, visit www.zentalis.com.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced a strategic collaboration with Tavros Therapeutics to enhance its oncology pipeline. This partnership aims to utilize Tavros' functional genomic discovery platform to identify new targeted small molecule drug candidates. Both CEOs expressed optimism about leveraging their technologies to produce safer and more effective cancer therapies. The agreement grants each company rights to any new products developed through this collaboration. This partnership could significantly advance Zentalis' development of innovative treatments for cancer patients.